The pooled analysis of seven trials within the ACCENT/IDEA consortium [36] explores the distinct prognostic implications of KRAS exon 2 submutations and the BRAF V600E mutation in stage III colon cancer. This evidence concerns the gene KRAS and colonic neoplasm.